新型选择性可溶性鸟苷酸环化酶激活剂MGV354在临床前模型中局部眼用给药后降低眼压
本研究在临床前模型中评估选择性可溶性鸟苷酸环化酶激活剂MGV354局部眼用给药后的降眼压效果。在色素兔和食蟹猴青光眼模型中,单次给药引起显著的剂量依赖性眼压降低20%至40%(对照为溶媒),降幅大于曲伏前列素。作者认为MGV354是一类新型sGC激活剂,其作为青光眼患者有效降眼压药物的潜力可在临床研究中进一步确定。
要点
- MGV354单次局部眼用给药在色素兔引起20%至40%的剂量依赖性眼压降低(对照为溶媒),持续至6小时。
- 在食蟹猴青光眼模型中单次给药后眼压降低持续24小时,每日一次给药降眼压作用维持至7天。
- MGV354降眼压幅度大于曲伏前列素,主要不良事件为轻至中度眼部充血。
核心结论
- MGV354是一类新型sGC激活剂,可在临床前青光眼模型中降低眼压。
- sGC激活剂作为青光眼患者有效降眼压药物的潜力可在临床研究中进一步确定。
研究设计与样本
- 在原发性人小梁网(hNTM)细胞中评估cGMP变化,并使用人sGC全长蛋白进行结合研究。
- 在兔和猴模型中局部眼用给予MGV354后进行眼部安全性、耐受性、暴露和疗效研究。
主要发现
- sGC在人眼和食蟹猴流出通路中高表达。
- MGV354对氧化型sGC的Bmax较还原型sGC高7倍,在hTM细胞中产生的cGMP较还原条件高8至10倍。
- 单次局部眼用MGV354引起显著的剂量依赖性眼压降低20%至40%(对照为溶媒),在色素兔持续至6小时,在食蟹猴青光眼模型给药后持续24小时。
- 在猴青光眼模型中每日一次给药后,MGV354诱导的降眼压作用维持至7天,且降幅大于曲伏前列素诱导的降眼压作用。
- 观察到的主要不良事件为轻至中度眼部充血。
临床怎么用
- 原文结论指出MGV354是一类新型sGC激活剂,可在临床前青光眼模型中降低眼压。
- 原文结论指出sGC激活剂作为青光眼患者有效降眼压药物的潜力可在临床研究中进一步确定。
局限性
- 原文结论指出sGC激活剂作为青光眼患者有效降眼压药物的潜力可在临床研究中进一步确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The nitric oxide/soluble guanylate cyclase/protein kinase G (NO/sGC/PKG) is known to be involved in the regulation of intraocular pressure (IOP) and may be dysregulated in glaucoma. The purpose is to demonstrate that the sGC activator MGV354 lowers IOP in a monkey model of glaucoma and could be considered as a possible new clinical drug candidate. METHODS: Changes to cGMP were assessed in primary human trabecular meshwork (hNTM) cells and binding studies were conducted using human sGC full-length protein. Ocular safety tolerability, exposure, and efficacy studies were conducted in rabbit and monkey models following topical ocular dosing of MGV354. RESULTS: sGC was highly expressed in the human and cynomolgus monkey outflow pathways. MGV354 had a 7-fold greater Bmax to oxidized sGC compared to that of reduced sGC and generated an 8- to 10-fold greater cGMP compared to that of a reduced condition in hTM cells. A single topical ocular dose with MGV354 caused a significant dose-dependent reduction of 20% to 40% (versus vehicle), lasting up to 6 hours in pigmented rabbits and 24 hours postdose in a cynomolgus monkey model of glaucoma. The MGV354-induced IOP lowering was sustained up to 7 days following once-daily dosing in a monkey model of glaucoma and was greater in magnitude compared to Travatan (travoprost)-induced IOP reduction. Mild to moderate ocular hyperemia was the main adverse effect noted. CONCLUSIONS: MGV354 represents a novel class of sGC activators that can lower IOP in preclinical models of glaucoma. The potential for sGC activators to be used as effective IOP-lowering drugs in glaucoma patients could be further determined in clinical studies.
引用
- Prasanna G, Ferrara L, Adams C, et al. A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing. Invest Ophthalmol Vis Sci. 2018. PMID: 29610853. doi:10.1167/iovs.18-23772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。